{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:55:03Z","timestamp":1781513703823,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co, Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Provincial Key of Medical Science Research of Hebei","award":["No. 20241673"],"award-info":[{"award-number":["No. 20241673"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05032-2","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T02:09:11Z","timestamp":1772071751000},"page":"11879-11887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of ivarmacitinib on swelling and tenderness in small and large joints and imaging changes in patients with moderate-to-severe RA: a post hoc analysis of a phase III clinical trial"],"prefix":"10.1007","volume":"399","author":[{"given":"Yuxiang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixue","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"7","key":"5032_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, Brancati S, Scaglione F (2020) JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules 10(7):1002","journal-title":"Biomolecules"},{"issue":"4","key":"5032_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103276","volume":"22","author":"M Benucci","year":"2023","unstructured":"Benucci M, Bernardini P, Coccia C, De Luca R, Levani J, Economou A, Damiani A, Russo E, Amedei A, Guiducci S, Bartoloni E, Manfredi M, Grossi V, Infantino M, Perricone C (2023) JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev 22(4):103276","journal-title":"Autoimmun Rev"},{"key":"5032_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070856","volume":"384","author":"P Brown","year":"2024","unstructured":"Brown P, Pratt AG, Hyrich KL (2024) Therapeutic advances in rheumatoid arthritis. BMJ 384:e070856","journal-title":"BMJ"},{"issue":"6","key":"5032_CR4","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","volume":"163","author":"B Chen","year":"2022","unstructured":"Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M (2022) Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study. Gastroenterology 163(6):1555\u20131568","journal-title":"Gastroenterology"},{"key":"5032_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221137127","volume":"14","author":"EI Ciofoaia","year":"2022","unstructured":"Ciofoaia EI, Pillarisetty A, Constantinescu F (2022) Health disparities in rheumatoid arthritis. Ther Adv Musculoskelet Dis 14:1759720x221137127","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"5032_CR6","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","volume":"5","author":"Collaborators GRA","year":"2023","unstructured":"Collaborators GRA (2023) Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 5(10):e594\u2013e610","journal-title":"Lancet Rheumatol"},{"issue":"10416","key":"5032_CR7","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P (2023) Rheumatoid arthritis. Lancet 402(10416):2019\u20132033","journal-title":"Lancet"},{"issue":"12","key":"5032_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.medcli.2023.07.014","volume":"161","author":"F D\u00edaz-Gonz\u00e1lez","year":"2023","unstructured":"D\u00edaz-Gonz\u00e1lez F, Hern\u00e1ndez-Hern\u00e1ndez MV (2023) Rheumatoid arthritis. Med Clin (Barc) 161(12):533\u2013542","journal-title":"Med Clin (Barc)"},{"issue":"12","key":"5032_CR9","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/rheumatology\/kes228","volume":"51","author":"L Dirven","year":"2012","unstructured":"Dirven L, van den Broek M, Kroon HM, Grillet BA, Han KH, Kerstens PJ, Huizinga TW, Lems WF, Allaart CF (2012) Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints. Rheumatology (Oxford) 51(12):2262\u20132268","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"5032_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3899\/jrheum.181089","volume":"46","author":"A Duarte-Garc\u00eda","year":"2019","unstructured":"Duarte-Garc\u00eda A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A (2019) Endorsement of the 66\/68 Joint Count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. J Rheumatol 46(8):996\u20131005","journal-title":"J Rheumatol"},{"issue":"3","key":"5032_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/25785826.2023.2183594","volume":"46","author":"H Kameda","year":"2023","unstructured":"Kameda H (2023) JAK inhibitors \u223c overview\u223c. Immunol Med 46(3):108\u2013111","journal-title":"Immunol Med"},{"issue":"3","key":"5032_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2025.102072","volume":"39","author":"DA Kellner","year":"2025","unstructured":"Kellner DA, Morris NT, Lee SM, Baker JF, Chu P, Ranganath VK, Kaeley GS, Yang HH (2025) Clinical utility of ultrasound and MRI in rheumatoid arthritis: an expert review. Best Pract Res Clin Rheumatol 39(3):102072","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"15","key":"5032_CR13","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.3390\/ijms25158327","volume":"25","author":"K Kie\u0142bowski","year":"2024","unstructured":"Kie\u0142bowski K, Plewa P, Bratborska AW, Bakinowska E, Pawlik A (2024) JAK inhibitors in rheumatoid arthritis: immunomodulatory properties and clinical efficacy. Int J Mol Sci 25(15):8327","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5032_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41232-023-00293-3","volume":"43","author":"M Komagamine","year":"2023","unstructured":"Komagamine M, Komatsu N, Ling R, Okamoto K, Tianshu S, Matsuda K, Takeuchi T, Kaneko Y, Takayanagi H (2023) Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss. Inflamm Regen 43(1):44","journal-title":"Inflamm Regen"},{"issue":"4","key":"5032_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y (2023) JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 32(4):333\u2013344","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"5032_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Sch\u00fclke S (2020) Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 9(4):880","journal-title":"Cells"},{"key":"5032_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108793","volume":"230","author":"S Liu","year":"2021","unstructured":"Liu S, Ma H, Zhang H, Deng C, Xin P (2021) Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clin Immunol 230:108793","journal-title":"Clin Immunol"},{"issue":"2","key":"5032_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard-2024-226385","volume":"84","author":"J Liu","year":"2025","unstructured":"Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, He X, Wu R, Yang L, Liu H, Duan X, Xu S, Luo H, Liu J, Xie Q, Mi C, Chen L, Zhang N, Gong H, Zhu J, Li Y, Wei H, Qian L, Wang J, Shi X, Jin H, Jiang Z, Xie X, Zhan F, Geng X, Zheng Z, Du Z, Dong G, Sun Y, Zeng X (2025) Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis 84(2):188\u2013200","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5032_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","volume":"98","author":"HA Miot","year":"2023","unstructured":"Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM (2023) JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol 98(5):656\u2013677","journal-title":"An Bras Dermatol"},{"key":"5032_CR20","doi-asserted-by":"publisher","first-page":"1759720x2210762","DOI":"10.1177\/1759720X221076211","volume":"14","author":"J Mucke","year":"2022","unstructured":"Mucke J, Krusche M, Burmester GR (2022) A broad look into the future of rheumatoid arthritis. Ther Adv Musculoskelet Dis 14:1759720x221076211","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"5032_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-015-0501-8","volume":"17","author":"AM Orbai","year":"2015","unstructured":"Orbai AM, Bingham CO 3rd (2015) Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep 17(4):28","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"5032_CR22","first-page":"1385","volume":"30","author":"M \u00d8stergaard","year":"2003","unstructured":"\u00d8stergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, Shnier R, O\u2019Connor P, Klarlund M, Emery P, Genant H, Lassere M, Edmonds J (2003) OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30(6):1385\u20131386","journal-title":"J Rheumatol"},{"issue":"1","key":"5032_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","volume":"478","author":"P Prasad","year":"2023","unstructured":"Prasad P, Verma S, Surbhi GNK, Chaturvedi V, Mittal SA (2023) Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem 478(1):69\u201388","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"5032_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.25259\/IJDVL_8_2023","volume":"89","author":"SP Raychaudhuri","year":"2023","unstructured":"Raychaudhuri SP, Raychaudhuri SK (2023) JAK inhibitor: introduction. Indian J Dermatol Venereol Leprol 89(5):688\u2013690","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"14","key":"5032_CR25","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3390\/jcm13144137","volume":"13","author":"F Salaffi","year":"2024","unstructured":"Salaffi F, Carotti M, Di Carlo M, Ceccarelli L, Farah S, Poliseno AC, Di Matteo A, Bandinelli F, Giovagnoni A (2024) Magnetic resonance imaging (MRI)-based semi-quantitative methods for rheumatoid arthritis: from scoring to measurement. J Clin Med 13(14):4137","journal-title":"J Clin Med"},{"key":"5032_CR26","unstructured":"Scott IC, Scott DL (2014) Joint counts in inflammatory arthritis. Clin Exp Rheumatol 32(5 Suppl 85):S-7\u201312"},{"key":"5032_CR27","doi-asserted-by":"crossref","unstructured":"Scott DL, Antoni C, Choy EH, Van Riel PC (2003) Joint counts in routine practice. Rheumatology (Oxford) 42(8):919\u2013923","DOI":"10.1093\/rheumatology\/keg235"},{"issue":"1","key":"5032_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, Porreca F (2021) The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum 51(1):278\u2013284","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"5032_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.berh.2011.10.002","volume":"25","author":"YK Tan","year":"2011","unstructured":"Tan YK, Conaghan PG (2011) Imaging in rheumatoid arthritis. Best Pract Res Clin Rheumatol 25(4):569\u2013584","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"5032_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen A, Spinelli FR, Telliez JB, O\u2019Shea JJ, Silvennoinen O, Gadina M (2024) JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol 20(10):649\u2013665","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"5032_CR31","volume":"10","author":"S Weissman","year":"2018","unstructured":"Weissman S, Alsheikh M, Kamar K, Breslin J, Khabut A, Maruf MG (2018) Non-insidious large joint manifestation of severe cachectic rheumatoid arthritis. Cureus 10(9):e3266","journal-title":"Cureus"},{"issue":"7","key":"5032_CR32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","volume":"161","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Gooderham M, Yang B, Wu J, Wu L, Loo WJ, Toth D, Sauder M, Li J, Chen A, Tao X, Lu J, Song Z, Han J, Li H, Li Y, Xu L, Zhang J (2025) Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial. JAMA Dermatol 161(7):688\u2013697","journal-title":"JAMA Dermatol"},{"issue":"5","key":"5032_CR33","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","volume":"89","author":"C Zhou","year":"2023","unstructured":"Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J (2023) A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol 89(5):911\u2013919","journal-title":"J Am Acad Dermatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05032-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:19:31Z","timestamp":1781511571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05032-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5032"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05032-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the relevant Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}